[Skip to Navigation]
November 1992

Treatment Trial of Oxiracetam in Alzheimer's Disease

Author Affiliations

From the Neurobehavioral Program, Department of Neurology, Emory University School of Medicine and the Wesley Woods Center (Drs R. C. Green, Goldstein, Auchus, J. Green, Hersch, and Karp and Mss Presley and Van Tuyl), and the Division of Biostatistics, Emory University School of Public Health (Dr Clark), Atlanta, Ga.

Arch Neurol. 1992;49(11):1135-1136. doi:10.1001/archneur.1992.00530350049018

• Twenty-four carefully assessed patients with probable Alzheimer's disease were enrolled in a double-blind, placebo-controlled treatment study of oxiracetam, a nootropic agent reported to improve memory performance in patients with dementia. A broad battery of neuropsychological tests failed to reveal any improvement in the treated group or in any treated patient when individual test scores were analyzed. These findings indicate that oxiracetam is ineffective in reducing cognitive impairment due to Alzheimer's disease.

Add or change institution